Jump to contents

Researcher Information

last modified：2024/11/21

Associate Professor　NANJO, Shigeki

Laboratory Website

Faculty, Affiliation

University Hospital

College and School Educational Field


Laboratory

Academic Background

【Degree】
MD

Career

(2007/04-2008/03)
(2008/04-2011/03)
(2011/04-2015/12)
(2015/12-2016/11)
(2016/12-2021/07)
(2016/12-)

Year & Month of Birth

Academic Society


Award


○Distinguished reviewer Award of Tanslational lung cancer research (2023/07/01)
○JRS Young Scientist Award(2021/11/20)
○JRS Young Scientist Award(2021/11/20)
○JRS Young Scientist Award(2021/11/20)
○JRS Young Scientist Award(2021/11/20)
○JRS Young Scientist Award(2021/11/20)
○JRS Young Scientist Award(2021/11/20)
○JRS Young Scientist Award(2021/11/20)
○JRS Young Scientist Award(2021/11/20)
○JRS Young Scientist Award(2021/11/20)

Specialities

Speciality Keywords

Research Themes

Books

Papers

  • 　Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer.　Shigeki Nanjo,Wei Wu,Niki Karachaliou,Collin M Blakely,Junji Suzuki,Yu-Ting Chou,Siraj M Ali,D Lucas Kerr,Victor R Olivas,Jonathan Shue,Julia Rotow,Manasi K Mayekar,Franziska Haderk,Nilanjana Chatterjee,Anatoly Urisman,Jia Chi Yeo,Anders J Skanderup,Aaron C Tan,Wai Leong Tam,Oscar Arrieta,Kazuyoshi Hosomichi,Akihiro Nishiyama,Seiji Yano,Yuriy Kirichok,Daniel Sw Tan,Rafael Rosell,Ross A Okimoto,Trever G Bivona　The Journal of clinical investigation　132　13　2022/07/01
  • 　Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer.　Shigeki Nanjo,Akito Hata,Chiyuki Okuda,Reiko Kaji,Hideaki Okada,Daisuke Tamura,Kei Irie,Hiroshi Okada,Shoji Fukushima,Nobuyuki Katakami　British journal of cancer　118　1　32　2018/01
  • 　MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer.　Shigeki Nanjo,Sachiko Arai,Wei Wang,Shinji Takeuchi,Tadaaki Yamada,Akito Hata,Nobuyuki Katakami,Yasunori Okada,Seiji Yano　Molecular cancer therapeutics　16　3　506　2017/03
  • 　High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells.　Shigeki Nanjo,Hiromichi Ebi,Sachiko Arai,Shinji Takeuchi,Tadaaki Yamada,Satsuki Mochizuki,Yasunori Okada,Mitsutoshi Nakada,Takashi Murakami,Seiji Yano　Oncotarget　7　4　3847　2016/01/26
  • 　In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.　Shigeki Nanjo,Takayuki Nakagawa,Shinji Takeuchi,Kenji Kita,Koji Fukuda,Mitsutoshi Nakada,Hisanori Uehara,Hiroshi Nishihara,Eiji Hara,Hidetaka Uramoto,Fumihiro Tanaka,Seiji Yano　Cancer science　106　3　244　2015/03

show all

  • 　Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.　Shigeki Nanjo,Tadaaki Yamada,Hiroshi Nishihara,Shinji Takeuchi,Takako Sano,Takayuki Nakagawa,Daisuke Ishikawa,Lu Zhao,Hiromichi Ebi,Kazuo Yasumoto,Kunio Matsumoto,Seiji Yano　PloS one　8　12　e84700　2013
  • 　Circulating tumor DNA analysis in patients with EGFR mutant lung cancer.　Shigeki Nanjo,Trever G Bivona　Journal of thoracic disease　10　Suppl 33　S4061-S4064　2018/11
  • 　Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts.　Jeffrey J Quinn,Matthew G Jones,Ross A Okimoto,Shigeki Nanjo,Michelle M Chan,Nir Yosef,Trever G Bivona,Jonathan S Weissman　Science (New York, N.Y.)　371　6532　2021/02/26
  • 　Development and validation of a method for gefitinib quantification in dried blood spots using liquid chromatography-tandem mass spectrometry: Application to finger-prick clinical blood samples of patients with non-small cell lung cancer.　Kei Irie,Saori Shobu,Seika Hiratsuji,Yuta Yamasaki,Shigeki Nanjo,Chiyuki Kokan,Akito Hata,Reiko Kaji,Katsuhiro Masago,Shiro Fujita,Yutaka Okada,Nobuyuki Katakami,Shoji Fukushima　Journal of chromatography. B, Analytical technologies in the biomedical and life sciences　1087-1088　1　2018/06/15
  • 　Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.　Sachiko Arai,Shinji Takeuchi,Koji Fukuda,Hirokazu Taniguchi,Akihiro Nishiyama,Azusa Tanimoto,Miyako Satouchi,Kaname Yamashita,Koshiro Ohtsubo,Shigeki Nanjo,Toru Kumagai,Ryohei Katayama,Makoto Nishio,Mei-Mei Zheng,Yi-Long Wu,Hiroshi Nishihara,Takushi Yamamoto,Mitsutoshi Nakada,Seiji Yano　Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer　15　5　752　2020/05
  • 　CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs.　Ross A Okimoto,Wei Wu,Shigeki Nanjo,Victor Olivas,Yone K Lin,Rovingaile Kriska Ponce,Rieko Oyama,Tadashi Kondo,Trever G Bivona　The Journal of clinical investigation　129　8　3401　2019/07/22
  • 　Clinical features and outcome of acute exacerbation of interstitial pneumonia: collagen vascular diseases-related versus idiopathic.　Ryo Tachikawa,Keisuke Tomii,Hiroyuki Ueda,Kazuma Nagata,Shigeki Nanjo,Ayako Sakurai,Kyoko Otsuka,Reiko Kaji,Michio Hayashi,Nobuyuki Katakami,Yukihiro Imai　Respiration; international review of thoracic diseases　83　1　20　2012
  • 　Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.　Akito Hata,Nobuyuki Katakami,Hiroshige Yoshioka,Shiro Fujita,Kei Kunimasa,Shigeki Nanjo,Kyoko Otsuka,Reiko Kaji,Keisuke Tomii,Masahiro Iwasaku,Akihiro Nishiyama,Hidetoshi Hayashi,Satoshi Morita,Tadashi Ishida　Lung cancer (Amsterdam, Netherlands)　74　2　268　2011/11
  • 　[Four cases of interstitial pneumonia associated with amyopathic dermatomyositis characterized by the anti-CADM-140 antibody].　Kazuma Nagata,Keisuke Tomii,Shigeki Nanjo,Mio Kubota,Ryo Tachikawa,Mari Nishio　Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society　49　1　30　2011/01
  • 　Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency.　Koushiro Ohtsubo,Daisuke Ishikawa,Shigeki Nanjo,Shinji Takeuchi,Tadaaki Yamada,Hisatsugu Mouri,Kaname Yamashita,Kazuo Yasumoto,Toshifumi Gabata,Osamu Matsui,Hiroko Ikeda,Yasushi Takamatsu,Sakae Iwakami,Seiji Yano　JOP : Journal of the pancreas　14　5　515　2013/09/10
  • 　[Two cases of effective S-1 monotherapy for patients with metastatic adenocarcinoma of the lung after multiple previous chemotherapies].　Akito Hata,Shigeki Nanjo,Kyoko Otsuka,Yoko Kida,Yoichiro Higashi,Reiko Kaji,Shiro Fujita,Nobuyuki Katakami　Gan to kagaku ryoho. Cancer & chemotherapy　36　5　807　2009/05
  • 　Androgen replacement therapy for cancer-related symptoms in male: result of prospective randomized trial (ARTFORM study).　Kouji Izumi,Hiroaki Iwamoto,Hiroshi Yaegashi,Takahiro Nohara,Kazuyoshi Shigehara,Yoshifumi Kadono,Shigeki Nanjo,Tadaaki Yamada,Koshiro Ohtsubo,Seiji Yano,Atsushi Mizokami　Journal of cachexia, sarcopenia and muscle　12　4　831　2021/08
  • 　Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.　Koji Fukuda,Shinji Takeuchi,Sachiko Arai,Ryohei Katayama,Shigeki Nanjo,Azusa Tanimoto,Akihiro Nishiyama,Takayuki Nakagawa,Hirokazu Taniguchi,Takeshi Suzuki,Tadaaki Yamada,Hiroshi Nishihara,Hironori Ninomiya,Yuichi Ishikawa,Satoko Baba,Kengo Takeuchi,Atsushi Horiike,Noriko Yanagitani,Makoto Nishio,Seiji Yano　Cancer research　79　7　1658　2019/04/01
  • 　Recurrence of renal cell carcinoma diagnosed using contralateral adrenal biopsy with endoscopic ultrasound-guided fine-needle aspiration.　Azusa Tanimoto,Shinji Takeuchi,Hiroshi Yaegashi,Hiroshi Kotani,Hidenori Kitai,Shigeki Nanjo,Hiromichi Ebi,Kaname Yamashita,Hisatsugu Mouri,Koushiro Ohtsubo,Hiroko Ikeda,Seiji Yano　Molecular and clinical oncology　4　4　537　2016/04
  • 　EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.　Takayuki Nakagawa,Shinji Takeuchi,Tadaaki Yamada,Hiromichi Ebi,Takako Sano,Shigeki Nanjo,Daisuke Ishikawa,Mitsuo Sato,Yoshinori Hasegawa,Yoshitaka Sekido,Seiji Yano　Cancer research　73　8　2428　2013/04/15
  • 　[A case of poorly-differentiated neuroendocrine carcinoma of the ascending colon with multiple liver metastases successfully treated with cisplatin and irinotecan].　Kaname Yamashita,Daisuke Ishikawa,Shigeki Nanjo,Shinji Takeuchi,Tadaaki Yamada,Hisatsugu Mouri,Koushiro Ohtsubo,Kazuo Yasumoto,Masashi Kumagai,Yoshimichi Ueda,Seiji Yano　Gan to kagaku ryoho. Cancer & chemotherapy　39　9　1427　2012/09
  • 　Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.　Akito Hata,Nobuyuki Katakami,Hiroshige Yoshioka,Jumpei Takeshita,Kosuke Tanaka,Shigeki Nanjo,Shiro Fujita,Reiko Kaji,Yukihiro Imai,Kazuya Monden,Takeshi Matsumoto,Kazuma Nagata,Kyoko Otsuka,Ryo Tachikawa,Keisuke Tomii,Kei Kunimasa,Masahiro Iwasaku,Akihiro Nishiyama,Tadashi Ishida,Yoshihiro Nishimura　Cancer　119　24　4325　2013/12/15
  • 　Development of an LC-MS/MS-based method for quantitation of osimertinib in human plasma and cerebrospinal fluid.　Kei Irie,Shigeki Nanjo,Akito Hata,Yuta Yamasaki,Yutaka Okada,Nobuyuki Katakami,Shoji Fukushima　Bioanalysis　11　9　847　2019/05
  • 　Androgen replacement therapy for cancer-related symptoms in male advanced cancer patients: study protocol for a randomised prospective trial (ARTFORM study).　Kouji Izumi,Kazuyoshi Shigehara,Takahiro Nohara,Kazutaka Narimoto,Yoshifumi Kadono,Shigeki Nanjo,Tadaaki Yamada,Koushiro Ohtsubo,Seiji Yano,Atsushi Mizokami　The journal of medical investigation : JMI　64　3.4　202　2017
  • 　[Safety of pemetrexed mono-therapy in elderly patients with non-small cell lung cancer].　Ayako Konishi,Noriaki Kitada,Shigeki Nanjo,Shoji Tanaka,Keisuke Tomii,Nobuyuki Katakami,Tohru Hashida　Gan to kagaku ryoho. Cancer & chemotherapy　39　10　1507　2012/10
  • 　[Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain].　Akito Hata,Nobuyuki Katakami,Yoshio Masuda,Shigeki Nanjo,Kyoko Otsuka,Reiko Kaji,Shiro Fujita,Shigeo Iwamori,Yuka Mifune,Hiromi Orita,Michiyo Fukae,Toshiyuki Yamatani　Gan to kagaku ryoho. Cancer & chemotherapy　38　3　415　2011/03
  • 　Amrubicin at a lower-dose with routine prophylactic use of granulocyte-colony stimulating factor for relapsed small-cell lung cancer.　Akito Hata,Nobuyuki Katakami,Shiro Fujita,Reiko Kaji,Shigeki Nanjo,Kyoko Otsuka,Yoko Kida,Yoichiro Higashi,Ryo Tachikawa,Michio Hayashi,Takashi Nishimura,Keisuke Tomii　Lung cancer (Amsterdam, Netherlands)　72　2　224　2011/05
  • 　Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.　Akito Hata,Nobuyuki Katakami,Shigeki Nanjo,Chiyuki Okuda,Reiko Kaji,Katsuhiro Masago,Shiro Fujita,Hiroshi Yoshida,Kota Zama,Yukihiro Imai,Yukio Hirata　Lung cancer (Amsterdam, Netherlands)　111　182　2017/09
  • 　Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.　Junya Nakade,Shinji Takeuchi,Takayuki Nakagawa,Daisuke Ishikawa,Takako Sano,Shigeki Nanjo,Tadaaki Yamada,Hiromichi Ebi,Lu Zhao,Kazuo Yasumoto,Kunio Matsumoto,Kazuhiko Yonekura,Seiji Yano　Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer　9　6　775　2014/06
  • 　Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.　Takayuki Nakagawa,Shinji Takeuchi,Tadaaki Yamada,Shigeki Nanjo,Daisuke Ishikawa,Takako Sano,Kenji Kita,Takahiro Nakamura,Kunio Matsumoto,Kenichi Suda,Tetsuya Mitsudomi,Yoshitaka Sekido,Toshimitsu Uenaka,Seiji Yano　Molecular cancer therapeutics　11　10　2149　2012/10
  • 　Methylation of Tumor Suppressive miRNAs in Plasma from Patients With Pancreaticobiliary Diseases.　Koushiro Ohtsubo,Kunio Miyake,Sachiko Arai,Koji Fukuda,Chiaki Suzuki,Hiroshi Kotani,Azusa Tanimoto,Akihiro Nishiyama,Shigeki Nanjo,Kaname Yamashita,Shinji Takeuchi,Seiji Yano　Cancer diagnosis & prognosis　2　3　378　2022
  • 　A novel approach for the non-invasive diagnosis of pulmonary nodules using low-depth whole-genome sequencing of cell-free DNA. 　Zhang B, Liang H, Liu W, Zhou X, Qiao S, Li F, Tian P, Li C, Ma Y, Zhang H, Zhang Z, Nanjo S, Russo A, Puig-Butillé JA, Wu K, Wang C, Zhao X, Yue D. 　Transl Lung Cancer Res.　11　10　2094-2110　2022/10/31
  • 　Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer.　Akito Hata,Nobuyuki Katakami,Shigeki Nanjo,Chiyuki Okuda,Reiko Kaji,Katsuhiro Masago,Shiro Fujita,Hiroshi Yoshida,Kota Zama,Yukihiro Imai,Yukio Hirata　Oncotarget　8　69　113807　2017/12/26
  • 　Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.　Azusa Tanimoto,Tadaaki Yamada,Shigeki Nanjo,Shinji Takeuchi,Hiromichi Ebi,Kenji Kita,Kunio Matsumoto,Seiji Yano　Oncotarget　5　13　4920　2014/07/15
  • 　[Cancer of unknown primary site with epidermal growth factor receptor mutation for which gefitinib proved effective].　Tadaaki Yamada,Koushiro Ohtsubo,Daisuke Ishikawa,Shigeki Nanjo,Shinji Takeuchi,Hisatsugu Mouri,Kaname Yamashita,Kazuo Yasumoto,Seiji Yano　Gan to kagaku ryoho. Cancer & chemotherapy　39　8　1291　2012/08
  • 　A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002).　Akito Hata,Nobuyuki Katakami,Shiro Fujita,Shigeki Nanjo,Jumpei Takeshita,Kosuke Tanaka,Toshihiko Kaneda,Akihiro Nishiyama,Takashi Nishimura,Atsushi Nakagawa,Kojiro Otsuka,Satoshi Morita,Yoshiko Urata,Shunichi Negoro　Cancer chemotherapy and pharmacology　75　6　1267　2015/06
  • 　Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.　Koji Fukuda,Sakiko Otani,Shinji Takeuchi,Sachiko Arai,Shigeki Nanjo,Azusa Tanimoto,Akihiro Nishiyama,Katsuhiko Naoki,Seiji Yano　Cancer science　112　9　3784　2021/06/19
  • 　Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.　Hirokazu Taniguchi,Shinji Takeuchi,Koji Fukuda,Takayuki Nakagawa,Sachiko Arai,Shigeki Nanjo,Tadaaki Yamada,Hiroyuki Yamaguchi,Hiroshi Mukae,Seiji Yano　Cancer science　108　1　53　2017/01
  • 　Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression　H. Kotani,H. Ebi,H. Kitai,S. Nanjo,K. Kita,T. G. Huynh,A. Ooi,A. C. Faber,M. Mino-Kenudson,S. Yano　ONCOGENE　35　27　3587　2016/07　
  • 　Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer.　Shinji Takeuchi,Koji Fukuda,Sachiko Arai,Shigeki Nanjo,Kenji Kita,Tadaaki Yamada,Eiji Hara,Hiroshi Nishihara,Hisanori Uehara,Seiji Yano　International journal of cancer　138　5　1281　2016/03/01
  • 　The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.　Takako Sano,Shinji Takeuchi,Takayuki Nakagawa,Daisuke Ishikawa,Shigeki Nanjo,Tadaaki Yamada,Takahiro Nakamura,Kunio Matsumoto,Seiji Yano　International journal of cancer　133　2　505　2013/07/15
  • 　Dose reduction or intermittent administration of erlotinib: which is better for patients suffering from intolerable toxicities?　Akito Hata,Shiro Fujita,Reiko Kaji,Shigeki Nanjo,Nobuyuki Katakami　Internal medicine (Tokyo, Japan)　52　5　599　2013
  • 　mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.　Daisuke Ishikawa,Shinji Takeuchi,Takayuki Nakagawa,Takako Sano,Junya Nakade,Shigeki Nanjo,Tadaaki Yamada,Hiromichi Ebi,Lu Zhao,Kazuo Yasumoto,Takahiro Nakamura,Kunio Matsumoto,Hiroshi Kagamu,Hirohisa Yoshizawa,Seiji Yano　PloS one　8　5　e62104　2013
  • 　Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.　Tadaaki Yamada,Shinji Takeuchi,Junya Nakade,Kenji Kita,Takayuki Nakagawa,Shigeki Nanjo,Takahiro Nakamura,Kunio Matsumoto,Manabu Soda,Hiroyuki Mano,Toshimitsu Uenaka,Seiji Yano　Clinical cancer research : an official journal of the American Association for Cancer Research　18　13　3592　2012/07/01

Conference Presentations

  • Treatment optimization of EGFR-mutated lung cancer CNS metastasis using CSF-tDNA(2023/03/17)
  • Co-mutation in splicing factor with EGFR mutations limits sensitivity to EGFR-TKIs ～Why are EGFR-TKIs less effective against EGFR L858R?～(2022/12/01)
  • Deficiency of splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer(conference：International EGFR-Driven Lung Cancer Meeting)(2022/03/08)
  • Deficiency of splicing factor RBM10 limits EGFR-TKI response in metastatic EGFR mutant lung cancer(2022/02/19)
  • Co-mutation in splicing factor with EGFR mutations limits sensitivity to EGFR-TKIs ～Why are EGFR-TKIs less effective against EGFR L858R?～(conference：The 25th Congress of the Asian Pacific Society of Respirology)(2021/11/20)

Others

Arts and Fieldwork

Patent

Theme to the desired joint research

Grant-in-Aid for Scientific Research

○「EGFR変異肺がんを共存変異で層別化する個別化医療の理論的基盤を形成する研究」(2023-2025)　
○「分子標的治療誘導性転移の新規分子機構の解明と予防法の確立」(2023-2025)　
○「EGFR変異肺がんにおいて併存するRBM10遺伝子変異の機能解析」(2021-2022)　

Competitive research funding,Contribution

Collaborative research,Consignment study

Classes (Bachelors)

○Post-CC OSCE(2021)

Classes (Graduate Schools)

○Seminar of Cancer Pharmacology(2023)
○Seminar of Cancer Pharmacology(2023)
○Seminar of Cancer Pharmacology(2022)
○Seminar of Cancer Pharmacology(2022)
○Seminar of Cancer Pharmacology(2022)
○Seminar of Cancer Pharmacology(2022)

International Project

International Students

Lecture themes

Others (Social Activities)

○Japan Swimming Federation(2022-2022)　19th FINA World Championships Japan team doctor

To Page Top